undamentalytics Newsletter
Sign in

20/20 Biolabs, Inc. (AIDX) stock

Add to watchlist

Add holding +

NASDAQ: AIDX Nasdaq Life Sciences Tools & Services

20/20 Biolabs, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$0.2

Price-to-sales vs peers

Base case. Range ~$0.2–$1.1. Sales per share times peers' typical price-to-sales; used only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.

20/20 Biolabs, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds12 adding, 5 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 117% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in 20/20 Biolabs, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 128% and a beta of 0.7 against the S&P 500.

Latest results: FY2026 Q2

Filed August 14, 2026
Earnings per share
-$0.26 against an average estimate of -$0.12: missed by 116.7%
Revenue
$1m, up 36.5% on a year earlier
Share reaction
-5.5% in the first session after the results on August 17, 2026, against -1.1% for the S&P 500

20/20 Biolabs' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+14.3%
  • 1 week+4.3%
  • 1 month-36.8%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 17, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Shareholder vote
  2. Announcement
  3. Shareholder vote
  4. Results
  5. Announcement
  6. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

20/20 Biolabs, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value 20/20 Biolabs, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.04 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: book value or earnings not available
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.2 ~$0.3–$1.1 Included, half weight
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$0.2 ~$0.2–$1.1 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare 20/20 Biolabs, Inc. with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.42 +45% $3m —
Next −$0.38 +10% $6m +96%

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.12 −$0.26 −116.7%
Mar 2026 −$0.10 −$0.28 −180.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
0.1%
of tradable shares
Days to cover
0.12
at average volume
Short interest, 1 month
−76%
to October 15, 2026
Held by institutions
4%
of shares
Held by insiders
15.6%
of shares
Employees
4
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
−42.6%
vs 200-day average
—
Volatility (1 year)
128%
Beta vs S&P 500
0.68

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
0 up, 3 down
typical move ±6.0%
After a week
0 up, 3 down
typical move ±12.2%
After a month
0 up, 3 down
typical move ±28.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 17, 2026 −5.5% −1.1% −5.5% −12.7%
May 20, 2026 −9.7% +1.2% −29.1% −54.5%
April 1, 2026 −2.7% +0.8% −2.1% −17.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2024 Dec 2024 2025 Dec 2025
Income
Revenue 1,752 2,045
Gross profit 360 605
EBITDA −5,561 −3,268
Operating income −5,677 −3,331
Net income −5,552 −3,739
Diluted EPS −$1.16 −$0.76
Growth (year on year)
Revenue — +16.7%
Margins
Gross margin 20.6% 29.6%
EBITDA margin −317.4% −159.8%
Operating margin −324.0% −162.9%
Net margin −316.8% −182.8%
Cash flow
Cash from operations −2,599 −1,920
Stock-based pay 2,176 516
Balance sheet
Cash 1,784 1,026
Total debt 0 694
Net debt (negative = net cash) −1,784 −332
Diluted shares 5m 5m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $6m
Short-term assets $5mLonger-term assets $1m
What it owes, and who funded it · $5m
Short-term liabilities $3mLonger-term liabilities $0mShareholders' equity $2m
  • Short-term assets cover short-term liabilities $5m of assets due within a year against $3m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $5m short-term assets against $412,641 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From 20/20 Biolabs, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
One Test $1.8M 88.2% ▲ 21.0%
Bio Check $152,047 7.4% ▼ 14.2%
CLI Ax $89,379 4.4% ▲ 6.2%

From 20/20 Biolabs, Inc.'s 10-K filed March 31, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$297,121
Institutions reporting
15
Shares held vs prior quarter
▲ 80.0%
Positions opened / closed
10 / 2

Top buyers and sellers, Q2 2026: 12 institutions bought and 5 sold ; the biggest buyer was HRT Financial LP (+89K shares) and the biggest seller Cresset Asset Management, LLC (−24K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Cresset Asset Management, LLC $131,995 240K 44.4% ▼ 9.2%
HRT Financial LP $49,000 89K 16.5% New
Vanguard Fiduciary Trust Co $28,648 52K 9.6% New
Geode Capital Management, LLC $27,012 49K 9.1% New
Atlantic Union Bankshares Corp $19,294 35K 6.5% New
Vanguard Capital Management LLC $13,492 25K 4.5% New
Citadel Advisors LLC $12,756 23K 4.3% ▲ 43.0%
Bank Of America Corp $7,150 13K 2.4% New
Susquehanna International Group, LLP $5,505 10K 1.9% New
Mcdonald Partners LLC $1,539 3K 0.5% New
Signaturefd, LLC $422 1K 0.1% New
Morgan Stanley $156 0K 0.1% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not 20/20 Biolabs, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 17, 2026
  • May 20, 2026
  • April 1, 2026

Recent SEC filings

Data status

When each part of this page on 20/20 Biolabs, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

20/20 Biolabs, Inc. in brief

What does 20/20 Biolabs, Inc. do?
20/20 Biolabs, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is 20/20 Biolabs, Inc.'s stock ticker?
20/20 Biolabs, Inc. trades under the ticker AIDX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are 20/20 Biolabs, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Cresset Asset Management, LLC, HRT Financial LP and Vanguard Fiduciary Trust Co. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.